Merck Return on Investment 1986-2025 | MRK

Current and historical return on investment (ROI) values for Merck (MRK) over the last 10 years.
Merck ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2025-06-30 $19.82B $83.03B 24.37%
2025-03-31 $20.40B $81.88B 25.45%
2024-12-31 $20.22B $80.83B 26.07%
2024-09-30 $14.16B $79.54B 18.83%
2024-06-30 $16.05B $78.37B 21.65%
2024-03-31 $4.91B $71.57B 6.75%
2023-12-31 $2.95B $71.32B 4.01%
2023-09-30 $8.15B $75.27B 10.95%
2023-06-30 $6.39B $72.81B 8.64%
2023-03-31 $16.47B $74.98B 22.34%
2022-12-31 $18.28B $74.80B 25.10%
2022-09-30 $18.55B $73.01B 25.98%
2022-06-30 $19.36B $72.00B 28.55%
2022-03-31 $15.99B $71.54B 24.92%
2021-12-31 $13.20B $68.95B 22.35%
2021-09-30 $6.07B $58.77B 11.14%
2021-06-30 $3.66B $57.42B 6.81%
2021-03-31 $4.40B $51.04B 8.32%
2020-12-31 $5.55B $50.76B 10.66%
2020-09-30 $7.37B $55.59B 14.30%
2020-06-30 $7.48B $53.90B 14.94%
2020-03-31 $8.50B $47.94B 17.28%
2019-12-31 $7.93B $48.74B 15.91%
2019-09-30 $12.33B $49.60B 25.02%
2019-06-30 $12.38B $50.51B 24.74%
2019-03-31 $11.19B $50.39B 22.12%
2018-12-31 $8.93B $46.69B 17.22%
2018-09-30 $8.12B $52.59B 14.98%
2018-06-30 $5.60B $52.73B 9.98%
2018-03-31 $5.86B $55.40B 10.06%
2017-12-31 $6.80B $55.92B 11.27%
2017-09-30 $3.77B $60.34B 6.04%
2017-06-30 $6.69B $61.42B 10.41%
2017-03-31 $5.82B $63.53B 8.86%
2016-12-31 $5.50B $64.58B 8.24%
2016-09-30 $8.44B $67.61B 12.47%
2016-06-30 $7.71B $67.09B 11.30%
2016-03-31 $7.79B $67.56B 11.27%
2015-12-31 $7.55B $68.60B 10.68%
2015-09-30 $7.12B $69.80B 10.12%
2015-06-30 $6.48B $70.71B 9.41%
2015-03-31 $6.15B $73.42B 9.04%
2014-12-31 $6.68B $67.49B 9.88%
2014-09-30 $7.05B $63.93B 10.22%
2014-06-30 $7.82B $67.11B 10.98%
2014-03-31 $7.90B $72.15B 10.89%
2013-12-31 $7.67B $72.87B 10.58%
2013-09-30 $7.73B $72.65B 10.71%
2013-06-30 $7.64B $72.63B 10.47%
2013-03-31 $8.94B $71.70B 12.25%
2012-12-31 $9.88B $71.72B 13.49%
2012-09-30 $9.91B $75.78B 13.50%
2012-06-30 $9.91B $72.73B 13.63%
2012-03-31 $9.54B $72.54B 13.06%
2011-12-31 $8.98B $72.47B 12.30%
2011-09-30 $6.54B $73.29B 8.97%
2011-06-30 $5.58B $73.71B 7.69%
2011-03-31 $4.62B $72.48B 6.41%
2010-12-31 $3.36B $72.29B 4.60%
2010-09-30 $3.56B $72.08B 4.80%
2010-06-30 $3.78B $71.50B 5.86%
2010-03-31 $3.76B $75.62B 6.91%
2009-12-31 $4.02B $77.58B 9.57%
2009-09-30 $5.57B $33.55B 19.28%
2009-06-30 $5.49B $30.92B 20.83%
2009-03-31 $5.63B $25.94B 22.80%
2008-12-31 $6.09B $25.11B 25.28%
2008-09-30 $6.37B $23.51B 27.31%
2008-06-30 $5.97B $24.19B 25.30%
2008-03-31 $5.86B $23.49B 24.98%
2007-12-31 $5.62B $22.10B 23.83%
2007-09-30 $4.33B $24.60B 18.16%
2007-06-30 $3.71B $23.61B 15.66%
2007-03-31 $3.69B $24.03B 15.48%
2006-12-31 $3.69B $23.11B 15.54%
2006-09-30 $4.42B $24.08B 18.62%
2006-06-30 $5.44B $24.06B 23.23%
2006-03-31 $5.63B $23.61B 24.30%
2005-12-31 $5.86B $23.10B 25.37%
2005-09-30 $5.95B $22.90B 26.08%
2005-06-30 $5.88B $23.06B 26.11%
2005-03-31 $6.52B $23.31B 29.37%
2004-12-31 $6.76B $21.98B 31.17%
2004-09-30 $7.44B $21.71B 34.81%
2004-06-30 $8.37B $21.86B 39.66%
2004-03-31 $8.28B $21.20B 37.80%
2003-12-31 $8.57B $20.67B 37.82%
2003-09-30 $8.91B $20.71B 38.30%
2003-06-30 $8.84B $25.00B 37.32%
2003-03-31 $9.09B $24.25B 39.78%
2002-12-31 $9.11B $23.08B 41.26%
2002-09-30 $8.97B $22.40B 41.68%
2002-06-30 $9.33B $21.61B 44.78%
2002-03-31 $9.37B $21.24B 46.77%
2001-12-31 $9.42B $20.85B 48.70%
2001-09-30 $9.88B $19.59B 52.72%
2001-06-30 $9.67B $18.42B 53.52%
2001-03-31 $9.58B $18.48B 54.70%
2000-12-31 $9.41B $18.43B 56.09%
2000-09-30 $9.05B $16.96B 55.66%
2000-06-30 $8.57B $16.16B 53.45%
2000-03-31 $8.20B $15.55B 51.11%
1999-12-31 $7.91B $16.39B 48.53%
1999-09-30 $7.67B $16.07B 47.28%
1999-06-30 $7.38B $16.19B 46.09%
1999-03-31 $6.99B $16.56B 44.45%
1998-12-31 $6.64B $16.02B 43.33%
1998-09-30 $5.97B $15.29B 40.27%
1998-06-30 $5.67B $15.01B 38.79%
1998-03-31 $5.61B $14.99B 38.67%
1997-12-31 $5.52B $13.96B 38.95%
1997-09-30 $5.47B $14.52B 39.16%
1997-06-30 $5.35B $14.55B 39.59%
1997-03-31 $5.16B $13.67B 39.41%
1996-12-31 $4.94B $13.13B 38.10%
1996-09-30 $4.95B $12.73B 38.18%
1996-06-30 $4.82B $12.84B 37.07%
1996-03-31 $4.70B $13.18B 36.53%
1995-12-31 $4.60B $13.11B 36.43%
1995-09-30 $4.06B $12.85B 32.74%
1995-06-30 $4.06B $12.28B 33.05%
1995-03-31 $4.10B $12.22B 33.61%
1994-12-31 $4.10B $12.29B 34.14%
1994-09-30 $4.52B $12.36B 38.59%
1994-06-30 $4.32B $11.89B 42.78%
1994-03-31 $4.06B $11.51B 47.77%
1993-12-31 $3.91B $11.14B 55.60%
1993-09-30 $3.72B $5.84B 66.06%
1993-06-30 $3.60B $5.51B 63.39%
1993-03-31 $3.55B $5.66B 61.34%
1992-12-31 $3.49B $5.50B 60.26%
1992-09-30 $3.44B $6.08B 59.64%
1992-06-30 $3.34B $5.91B 60.03%
1992-03-31 $3.22B $5.70B 60.66%
1991-12-31 $3.11B $5.41B 63.03%
1991-09-30 $3.00B $5.24B 65.69%
1991-06-30 $2.89B $4.90B 68.32%
1991-03-31 $2.77B $4.18B 70.08%
1990-12-31 $2.65B $3.96B 69.61%
1990-09-30 $2.53B $3.86B 67.73%
1990-06-30 $2.43B $3.81B 67.10%
1990-03-31 $2.32B $3.61B 66.56%
1989-12-31 $2.24B $3.64B 66.44%
1989-09-30 $2.15B $3.44B 66.98%
1989-06-30 $2.05B $3.24B 66.37%
1989-03-31 $1.95B $3.15B 65.79%
1988-12-31 $1.87B $3.00B 66.79%
1988-09-30 $1.77B $2.95B 67.57%
1988-06-30 $1.64B $2.79B 62.16%
1988-03-31 $1.51B $2.45B 55.59%
1987-12-31 $1.37B $2.28B 48.65%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $270.018B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12